Alternative modalities of administering amphotericin B: current issues

Numerous studies performed in the field of antifungal therapy during the last decade have resulted in major developments in new modalities of administering amphotericin B including liposomes or other lipid vehicles. Current data available are very encouraging and several preparations are already commercially available in some countries. An improved therapeutic index has been shown in humans but large comparative trials are still needed to establish the definite role and indications of the various preparations as well as the optimal therapeutic regimens. These studies will make a significant contribution to improving the prognosis of patients predisposed to life threatening invasive fungal infections.